secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001356576-24-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q2 revenues up 24% to $168.3M; Qelbree sales surge 92%; raises FY2024 guidance
--------------------------------------------------------------------------------

- Total Q2 revenues $168.3M (+24% YoY); Qelbree net sales $59.4M (+92% YoY); GOCOVRI $31.7M (+10% YoY)
- Operating income $22.6M; adjusted operating earnings $45.5M, up from $10.0M in Q2 2023
- Raising full-year 2024 guidance for total revenues and operating earnings (GAAP and non-GAAP)
- Resubmitted NDA for apomorphine infusion device (SPN-830) for Parkinson's motor fluctuations
- Phase 2b trial of SPN-820 for TRD expected topline data H1 2025; Phase 2 open-label MDD data by end 2024

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000049/0001356576-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000049/supn-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer